Achieving Lean Processing With Single-Use Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Achieving Lean Processing With Single-Use Systems


Pharmaceutical Technology Europe


The process should also scale up accurately, enable straightforward validation and be robust during continued use at industrial scale. Finally, the economic objectives for the process must be met and constraints such as process time, unit operation size, or buffer use must be observed.

Once TFF processing is complete, all of the product must be removed from the system. There are several factors that can contribute to an optimised productrecovery strategy including:

  • lines should slope to a low-point recovery port
  • the tank, with a sloped bottom, should be mounted above the feed pump
  • a high-point air port for blowdown low pressure (~ 5 psig) should be included
  • a retentate-line buffer entry for buffer displacement should be included.

Product recovery will also be simpler from systems with a low minimum working volume because more product can be pumped out of the recycle tank, and there will be less volume throughout the lines and membranes. The minimum volume at which the system can operate must take into account the required process flow rate, and avoid causing significant turbulence or any air entrapment in the process fluid. It must also account for volume in the piping, valves, instruments, membranes and some minimal volume in the recycle tank.

High quality and purity

To ensure high product quality, the TFF system should be designed to avoid air–liquid interfaces and vortexing in the recycle tank, which can damage proteins. Vortexing can be reduced with proper agitator placement and design, and use of a vortex breaker at the tank outlet. Additionally, a sub-surface retentate return to the recycle tank that minimises turbulence will prevent air entrainment. Careful feed pump selection can also help protect product quality by eliminating cavitation.

The system must be designed to maximise removal of contaminants during diafiltration, sanitising and flushing to ensure high-product purity. Product purity is enhanced by minimising dead legs and contamination points, and avoiding flexible lines that are longer than necessary. A well-mixed process stream is also critical, and depends on agitator design and placement for mixing at all volumes, a retentate dip tube return designed to avoid short-circuiting, and a diafiltration bufferstream entry on the retentate line.

Impact of single-use on fill–finish

Traditional fill–finish systems are fixed systems that use complex component assemblies requiring operation and cleaning in a controlled, aseptic environment, using CIP/SIP, time pressure and piston pumps for operation. This presents a number of challenges resulting from stringent requirements for flowpath integrity and sterility, operational safety and efficiency, and fill accuracy. Because of the intensive use of stainless steel components, traditional fill–finish facilities are considered inflexible, with long change-out times and high operating costs because of CIP, SIP, labour and facility costs.

Case study

A single-use fill–finish solution (Mobius, Merck Millipore) was implemented by a pandemic flu vaccine manufacturer at an existing filling facility. With a product such as a pandemic flu vaccine, the speed and efficiency of the filling unit operation are critical to meet market demand. The manufacturer's goal in evaluating single-use fill–finish was to increase production without increasing its manufacturing footprint.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here